GLP1R and diabetic kidney disease: Diabetic nephropathy was alleviated by GLP-1 via inhibition of inflammatory activities such as MAPK and NF-κB phosphorylation, contributing to anti-inflammatory effects on podocytes and tubular cells, thereby reducing glomerulosclerosis and renal tubulointerstitial injuries [140,145].